Technical Articles

Reading peptide documentation: identity, purity, content and COA

How to distinguish specifications, batch results, assay and microbiological attributes.

2026-09-09 · 2 min read

Editorial educational content. Specialist review is not claimed; consult the original references and limitations.

Understand what the test answers

Useful documentation starts with a match: product, variant, batch and version must refer to the correct material. Before comparing percentages, determine what was measured. Identity, chromatographic purity, assay, water and counterions address different questions; a single number cannot summarize them all.

A chromatogram shows an analytical response under defined conditions. Retention time, integration, method and detector all affect interpretation. A main peak does not automatically make every other component detectable or reveal the vial's complete actual content.

Complementary techniques

HPLC and related methods separate components under chromatographic conditions. Mass spectrometry provides another perspective on observed species and masses. Combined methods can strengthen an assessment of identity and impurities, but suitability depends on the method, sample and defined criteria.

ICH Q2(R2), available through the FDA, addresses validation of analytical procedures. This differs from recognizing a logo or acronym in a PDF: request enough information to understand the purpose and suitability of the procedure used.

A COA is not a universal seal

A certificate of analysis should be associated with its batch and issuer. Check the title, identification, version, dates, tests, results and criteria. Where possible, compare with the original document and confirm provenance through the registered channel. Finding an identifier on a website establishes that a record exists; it does not independently authenticate a physical package.

AspectWhat to check
IdentityMatching compound, form and method
PurityResult definition and analytical conditions
ContentCalculation basis and reported unit
TraceabilityProduct, variant, batch, version and issuer
AccessPublic, restricted or available on request

Sterility and endotoxins

FDA guidance separately addresses pyrogen/endotoxin testing and controls related to sterility. A chromatographic-purity result does not replace those tests. High purity alone does not establish suitability for human use.

Storage and release

Storage and transport conditions should come from the record applicable to the material. Do not extrapolate one sequence's stability to all others or assume that a cold-chain service was contracted. When requesting documents, describe the laboratory purpose and evidence needed so the team can confirm availability and scope before quotation.

Sources and verification scope

Official / regulatory source · Q02

Q2(R2) Validation of Analytical Procedures ↗

FDA / ICH

Source details (original language)
Scope
Validation framework for analytical procedures
Document section
Final guidance summary
Limitations
Method validation does not certify this company or establish a result for a catalog lot.
Claim verification date
2026-09-09
Official / regulatory source · Q03

Pyrogen and Endotoxins Testing: Questions and Answers ↗

FDA

Source details (original language)
Scope
Separate microbiological/pyrogen-related testing considerations
Document section
Guidance scope
Limitations
Chromatographic purity is not an endotoxin or sterility test.
Claim verification date
2026-09-09
Official / regulatory source · Q04

Current Good Manufacturing Practice: production and process controls ↗

FDA

Source details (original language)
Scope
Testing and control context for products claimed sterile
Document section
Sterility and special testing requirements
Limitations
No claim that catalog materials are sterile or approved for human use.
Claim verification date
2026-09-09
Scientific publication · S04

Therapeutic peptides: current applications and future directions ↗

Wang et al. · Signal Transduction and Targeted Therapy

Source details (original language)
Scope
Review of therapeutic peptide development
Document section
Introduction; production, modification and applications
Limitations
Historical review, not validation of products or batches. More than 80 approved drugs is a 2022 literature statement.
Claim verification date
2026-09-09

Related commercial identities

Related research concerns the compound; it does not establish use of our product or lot in the study.

Related reading